MIRA · Mira Pharmaceuticals, Inc.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

Each restricted stock unit represents a right to receive one share of Issuer's common stock.

The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. All of the RSU shall vested on the Grant Date.

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Represents grants of options with underlying shares of Common Stock under the Plan, for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The options hereunder vested upon issuance.

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each.

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each.

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Represents exercise of 234,595 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on March 26, 2024, with 50% of such options vesting on the six-month anniversary date of the grant, and the remaining half vesting on the one-year anniversary date of the grant, pursuant to a grant under the Plan at an exercise price of $1.16 each.

Represents exercise of 379,000 stock options to purchase Common Stock under the Plan that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.84 each.

Represents 2,685,456 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc.

Represents 22,378 restricted shares of common stock, par value $0.0001 of the Issuer issued as compensation for the Issuer's acquisition of SKNY Pharmaceuticals, Inc.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on September 15, 2025.

The board of directors of the Company approved to reprice the options from its previous exercise price of $6.50 to $1.38. All of the other terms of the option remain unchanged.

The options were previously issued to the Reporting Person on August 17, 2023, and are now fully vested.

The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on September 15, 2025.

The board of directors of the Company approved to reprice the options from its previous exercise price of $5.00 to $1.38. All of the other terms of the option remain unchanged.

The options were previously issued to the Reporting Person on April 28, 2023, and are now fully vested.

Represents 62,500 RSUs vesting immediately, granted and issued to the Reporting Person from the Issuer's 2022 Omnibus Incentive Plan in connection with the Reporting Person's achievement of certain milestones pursuant to the Reporting Person's Executive Incentive Compensation Plan.

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance.

Represents the grant of Issuer's common stock, par value $0.0001 ("Common Stock") that should have been reported on Form 4.

Represents grants of RSUs with underlying shares of Common Stock under the Issuer's 2024 Omnibus Equity Incentive Plan (the "Plan"), for awards granted in accordance with the Issuer's CEO's Long-Term Incentive Plan. The RSUs hereunder vested upon issuance.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 25,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 150,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six- and 12-month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). Half of the shares subject to the option shall vest on the Grant Date and the remaining half of the shares subject to the option shall vest six months after the Grant Date.

Represents 2,000,000 stock options that were issued to the Reporting Person on December 6, 2024 under the Plan. Half of the shares subject to the option shall vest on the Grant Date and the remaining half of the shares subject to the option shall vest six months after the Grant Date.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 50,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Represents 25,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each.

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

The RSUs were issued to the Reporting Person on the Grant Date, pursuant to the Plan. Half of the shares subject to the RSU shall vest on the Grant Date and the remaining half of the shares subject to the RSU shall vest six months after the Grant Date.

Represents 500,000 RSUs that were issued to the Reporting Person on December 6, 2024 under the Plan. Half of the shares subject to the RSU shall vest on the Grant Date and the remaining half of the shares subject to the RSU shall vest six months after the Grant Date.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.

The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

25,000 stock options were issued to the Reporting Person on the Grant Date, pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the Reporting Person on 8/20/2024.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions.

The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the Reporting Person on 8/20/2024.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions.

As trustee of the Bay Shore Trust and the Celeste J Williams Lifetime QTIP Trust, Mr. McNulty has sole voting and dispositive power over the shares held by each trust, and, as a result is deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities held by the trusts. The address for the Bay Shore Trust is 900 West Platt Street, Suite 200, Tampa, Florida, 33606.

The exercise price of the stock options issued to the Reporting Person is equal to the Nasdaq Official Closing Price of the Issuer's common stock on June 18, 2024, the date of the grant.

The stock options were issued to the Reporting Person on June 18, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"), and in accordance with the terms of a consulting agreement dated June 18, 2024, by and between the Reporting Person and MIRA Pharmaceuticals, Inc. The stock options will vest in three equal tranches, with the first tranche vesting immediately on the grant date of June 18, 2024, the second tranche vesting on December 18, 2024, and the final tranche vesting on June 18, 2025.

Represents (i) 25,000 stock options that were issued to the Reporting person on March 25, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $1.16 each and (ii) 16,666 stock options that were issued to the Reporting Person on June 18, 2024, that were vested in full and became exercisable on the same date, pursuant to a grant under the Plan at an exercise price of $0.71 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on May 28, 2024.

The stock options were issued to the Reporting Person on May 28, 2024, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). The stock options vested in full and became exercisable immediately upon issuance on the grant date, May 28, 2024.

Represents 50,000 stock options that were issued to the Reporting Person on April 28, 2023 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each, (ii) 150,000 stock options that were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each, (iii) 50,000 stock options that were issued to the Reporting Person on August 17, 2023 that vested in full and became exercisable on April 28, 2024, pursuant to a grant under the Issuer's Plan at an exercise price of $6.50 each, and (iv) 379,000 stock options that were issued to the Reporting Person on May 28, 2024 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $0.84 each.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

These securities are directly owned by Mr. Aminov.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on March 26, 2024.

The options were granted under the Issuer's 2022 Amended and Restated Omnibus Incentive Plan (the "Plan") whereby 50% of such incentive options, or 75,000 options, will vest on the six month anniversary of the of the grant, or September 26, 2024, and the remaining 50% will vest on the first anniversary of the grant date, March 26, 2025.

Represents (i) 3,334 stock options that were issued to the Reporting Person under the Plan that became exercisable on June 15, 2022 at an exercise price of $5.00 (ii) 3,333 stock options that were issued to the Reporting Person under the Plan that became exercise on June 15, 2023 at an exercise price of $5.00 each, (iii) 15,566 stock options were issued to the Reporting Person on April 28, 2023, pursuant to a grant under the Issuer's Plan which vested in full on April 28, 2024 at an exercise price of $6.50 each, (iv) 15,566 stock options were issued to the Reporting Person on April 28, 2023, pursuant to a grant under the Issuer's Plan which will vest in full on April 28, 2024 at an exercise price of $6.50 each (v) 20,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each.

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on March 26, 2024.

The options were granted under the Issuer's 2022 Amended and Restated Omnibus Incentive Plan (the "Plan") whereby 50% of such incentive options, or 150,000 options, will vest on the six month anniversary of the of the grant, or September 26, 2024, and the remaining 50% will vest on the first anniversary of the grant date, March 26, 2025.

Represents 50,000 stock options that were issued to the Reporting Person on April 28, 2023 that were vested in full and became exercisable on the same date, pursuant to a grant under the Issuer's Plan at an exercise price of $5.00 each, (ii) 150,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17,2023 at an exercise price of $6.50 each and (iii) 50,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which will vest in full on April 28. 2024 at an exercise price of $6.50 each.

The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025.

The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025.

The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025.

The options were granted under the Issuer's 2022 Omnibus Incentive Plan whereby 50% of such options, or 25,000 options, vested immediately on the grant date of March 25, 2024, and the remaining 50% vest on the first anniversary of the grant date, March 25, 2025.

These securities are owned directly by a trust for which Mr. McNulty serves as trustee. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.

These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Mr. McNulty as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.

These securities are owned directly by a trust for which Mr. McNulty serves as trustee. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.

These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Mr. McNulty as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.

These securities are owned directly by a trust for which Mr. McNulty serves as trustee. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.

These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Mr. McNulty as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.